Abstract
Cytochrome P450 proteins (CYP450s) are membrane-associated haem proteins that metabolize physiologically important compounds in many species of microorganisms, plants and animals. Mammalian CYP450s recognize and metabolize diverse xenobiotics such as drug molecules, environmental compounds and pollutants1. Human CYP450 proteins CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 are the major drug-metabolizing isoforms, and contribute to the oxidative metabolism of more than 90% of the drugs in current clinical use2. Polymorphic variants have also been reported for some CYP450 isoforms, which has implications for the efficacy of drugs in individuals, and for the co-administration of drugs. The molecular basis of drug recognition by human CYP450s, however, has remained elusive. Here we describe the crystal structure of a human CYP450, CYP2C9, both unliganded and in complex with the anti-coagulant drug warfarin. The structure defines unanticipated interactions between CYP2C9 and warfarin, and reveals a new binding pocket. The binding mode of warfarin suggests that CYP2C9 may undergo an allosteric mechanism during its function. The newly discovered binding pocket also suggests that CYP2C9 may simultaneously accommodate multiple ligands during its biological function, and provides a possible molecular basis for understanding complex drug–drug interactions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anzenbacher, P. & Anzenbacherova, E. Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 58, 737–747 (2001)
Hodgson, J. ADMET–turning chemicals into drugs. Nature Biotechnol. 19, 722–726 (2001)
Li, H. & Poulos, T. L. conformational dynamics in cytochromeP450-substrate interactions. Biochimie 78, 695–699 (1996)
Li, H. & Poulos, T. L. The structure of the cytochrome P450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nature Struct. Biol. 4, 140–146 (1997)
Schlichting, I., Jung, C. & Schulze, H. Crystal structure of cytochrome P-450cam complexed with the (1S)-camphor enantiomer. FEBS Lett. 415, 253–257 (1997)
Podust, L. M., Poulos, T. L. & Waterman, M. R. Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl Acad. Sci. USA 98, 3068–3073 (2001)
Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F. & McRee, D. E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell 5, 121–131 (2000)
Ibeanu, G. C. et al. Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. J. Biol. Chem. 271, 12496–12501 (1996)
Melet, A. et al. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch. Biochem. Biophys. 409, 80–91 (2003)
Haines, D. C., Tomchick, D. R., Machius, M. & Peterson, J. A. Pivotal role of water in the mechanism of P450BM-3. Biochemistry 40, 13456–13465 (2001)
Ridderstrom, M. et al. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem. Biophys. Res. Commun. 270, 983–987 (2000)
de Groot, M. J., Alex, A. A. & Jones, B. C. Development of a combined protein and pharmacophore nodel for cytochrome P450 2C9. J. Med. Chem. 45, 1983–1993 (2002)
Mancy, A., Broto, P., Dijols, S., Dansette, P. M. & Mansuy, D. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34, 10365–10375 (1995)
Jones, B. C. et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab. Dispos. 24, 260–266 (1996)
Lewis, D. F. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. Biochem. Pharmacol. 60, 293–306 (2000)
Takahashi, H. & Echizen, H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40, 587–603 (2001)
Kaminsky, L. S. & Zhang, Z. Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67–74 (1997)
Haining, R. L. et al. Enzymatic determinants of the substrate specificity of CYP2C9: role of B′-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry 38, 3285–3292 (1999)
Modi, S., Sutcliffe, M. J., Primrose, W. U., Lian, L. Y. & Roberts, G. C. The catalytic mechanism of cytochrome P450 BM3 involves a 6 Å movement of the bound substrate on reduction. Nature Struct. Biol. 3, 414–417 (1996)
Modi, S. et al. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 36, 4461–4470 (1997)
Nave, C. Radiation damage in protein crystallography. Radiat. Phys. Chem. 45, 483–490 (1995)
Hlavica, P. & Lewis, D. F. Allosteric phenomena in cytochrome P450-catalyzed monooxygenations. European Journal of Biochemistry 268, 4817–4832 (2001)
Tang, W. & Stearns, R. A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug Metab. 2, 185–198 (2001)
Hutzler, J. M., Hauer, M. J. & Tracy, T. S. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. 29, 1029–1034 (2001)
Hutzler, J. M., Wienkers, L. C., Wahhlstrom, J. L., Carlson, T. J. & Tracy, T. S. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch. Biochem. Biophys. 410, 16–24 (2003)
Stresser, D. M., Ackermann, J. M., Miller, V. P. & Crespi, C. L. Fluorometric cytochromes P450 2C8, 2C9 and 2C19 inhibition assays 〈http://www.gentest.com/〉.
Hemeryck, A., De Vriendt, C. & Belpaire, F. M. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur. J. Clin. Pharmacol. 54 (12), 947–951 (1999)
Leslie, A. G. W. MOSFLM. Joint CCP4 and EESF-EACMB Newsletter on Protein Crystallography 26 (SERC Daresbury Laboratory, Warrington, 1992)
Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50, 157–163 (1994)
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 50, 760–763 (1997)
Acknowledgements
We thank R. Mallender, L. Vuillard, S. Rich and S. Kirton for assistance with protein production, crystallization, characterization, analysis and modelling, and R. Carr, D. Cross, C. Murray and G. Williams for valuable discussions. We acknowledge the European Synchrotron Radiation Facility for provision of synchrotron radiation facilities and would like to thank the industrial user support group for assistance. The authors are grateful to F. W. Dahlquist for provision of the pCWOri + expression vector.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Williams, P., Cosme, J., Ward, A. et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464–468 (2003). https://doi.org/10.1038/nature01862
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature01862
This article is cited by
-
Warfarin Tautomers in Solution: A Structural, Computational and Thermodynamic Study
Journal of Chemical Crystallography (2024)
-
Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management
Scientific Reports (2023)
-
The past decade of Genentech experience in elucidation of novel reaction mechanisms in drug metabolism
Medicinal Chemistry Research (2023)
-
Unraveling the Interaction Mechanism of the Compounds From Cladophora sp to Recognize Prospective Larvicidal and Bactericidal Activities: In vitro and In Silico Approaches
Molecular Biotechnology (2023)
-
The protein conformational basis of isoflavone biosynthesis
Communications Biology (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.